Skip to main content
. 2015 Sep 25;5:14089. doi: 10.1038/srep14089

Figure 1. The strategy for developing an in situ metabolomics method to discover diagnostic biomarkers for a rapid, direct and label-free molecular histopathological diagnosis of cancer.

Figure 1

(ROIs: regions of interest; HDFE: histology-defined features extraction; MVSA: multivariate statistical analysis, AC: adenocarcinoma, SCC: squamous cell carcinoma; Poorly: poorly differentiated lung cancer; M/W: moderate/well-differentiated lung cancer)